Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The role of driver mutations in the epigenome of childhood brain tumours
FY 2015-16
Summary
Mutations in histone 3 are frequently recurrent in childhood brain tumours. They are thought to promote tumourigenesis through the dysregulation of histone modifications that control epigenetic states during differentiation of neural lineages. The presence of one of the substitutions lysine 27 to methionine (K27M) or glycine 34 to arginine or valine (G34R/V) in histone 3 define distinct biological and clinical characteristics of pediatric glioblastomas, in which these are thought to be driver mutations. The mechanism of how G34R/V mutations drive tumourigenesis is poorly understood. We aim to characterize their mechanism of action by introduction of these mutations in normal human neural stem cells that are a potential cell of origin of glioblastoma. The CRISPR-Cas9 gene editing technique allows us to efficiently introduce mutations in the endogenous gene where these oncogenic mutations are found; H3F3A . Cell lines carrying G34R/V mutations will be derived and characterized by functional analysis of the epigenome, focusing on methylation of histone 3 lysine 36 that has been shown to be altered in tumours. This will comprise chromatin immunoprecipitation sequencing and profiling of the transcriptome and DNA methylation patterns. Mutant lines will also be examined for markers of proliferation and apoptosis to relate changes in the epigenome to cellular traits associated with oncogenic transformation. This will describe in detail the effect of these mutations on human neural stem cells and potentially illuminate the unique biological determinants that define this subgroup of tumours. This has considerable value in identifying therapeutic targets to treat this deadly disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
349823
Name
Krug Brian M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of driver mutations in the epigenome of childhood brain tumours
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genetics; Crispr Gene Editing; Epigenomics; Histone Methylation; Pediatric Glioblastoma; Stem Cells
Abstract
Mutations in histone 3 are frequently recurrent in childhood brain tumours. They are thought to promote tumourigenesis through the dysregulation of histone modifications that control epigenetic states during differentiation of neural lineages. The presence of one of the substitutions lysine 27 to methionine (K27M) or glycine 34 to arginine or valine (G34R/V) in histone 3 define distinct biological and clinical characteristics of pediatric glioblastomas, in which these are thought to be driver mutations. The mechanism of how G34R/V mutations drive tumourigenesis is poorly understood. We aim to characterize their mechanism of action by introduction of these mutations in normal human neural stem cells that are a potential cell of origin of glioblastoma. The CRISPR-Cas9 gene editing technique allows us to efficiently introduce mutations in the endogenous gene where these oncogenic mutations are found; H3F3A . Cell lines carrying G34R/V mutations will be derived and characterized by functional analysis of the epigenome, focusing on methylation of histone 3 lysine 36 that has been shown to be altered in tumours. This will comprise chromatin immunoprecipitation sequencing and profiling of the transcriptome and DNA methylation patterns. Mutant lines will also be examined for markers of proliferation and apoptosis to relate changes in the epigenome to cellular traits associated with oncogenic transformation. This will describe in detail the effect of these mutations on human neural stem cells and potentially illuminate the unique biological determinants that define this subgroup of tumours. This has considerable value in identifying therapeutic targets to treat this deadly disease.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Krug, Brian M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~